Results 201 to 210 of about 24,414 (214)

Antitumor activity and molecular mechanism of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition

Naunyn-Schmiedeberg's Archives of Pharmacology, 2022
Huimin Sun, W. Meng, Jie Zhu, Lu Wang
semanticscholar   +1 more source

Proprotein convertase subtilisin/kexin type 9 in human disease

2011
Cardiovascular disease (CVD) is the leading cause of death in the 21st century. Among risk factors, hypercholesterolemia and abdominal obesity are directly linked to premature development of atherosclerosis. Familial hypercholesterolemia, commonly due to low-density lipoprotein receptor (LDLR) deficiency, is known to cause premature atherosclerosis and
openaire   +1 more source

Proprotein convertase subtilisin/kexin type 9 in rheumatoid arthritis.

Clinical and experimental rheumatology, 2017
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that regulates cholesterol metabolism through low-density lipoprotein receptor degradation and that has been linked with cardiovascular risk. The purpose of the present study was to examine whether PCSK9 levels are related to both abnormalities in the lipid profile and the ...
Ivan, Ferraz-Amaro, Raquel, López-Mejías, Begoña, Ubilla, Fernanda, Genre, Beatriz, Tejera-Segura, Antonia M, de Vera-González, Agustín F, González-Rivero, Jose M, Olmos, Jose L, Hernández, Javier, Llorca, Miguel A, González-Gay   +10 more
openaire   +1 more source

Proprotein convertase subtilisin/kexin type 9-inhibition across different patient populations

Current Opinion in Lipidology
Purpose of review Monoclonal antibodies (mAb) targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) have been established in cardiovascular risk prevention. The purpose of this review is to summarize the effects of PCSK9 inhibitors across different patient populations. Recent findings
Paulina Elena, Stürzebecher, Ulrich, Laufs   +1 more
openaire   +2 more sources

Proprotein convertase subtilisin/kexin 9 (PCSK9)

Science-Business eXchange, 2008
openaire   +1 more source

Hemmung der Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)

CardioVasc, 2013
Valérie Pavlicek, Daniel Urban, Ulrich Laufs   +2 more
openaire   +1 more source

Regulation of proprotein convertase subtilisin/kexin type 9: Therapeutical perspectives

Atherosclerosis, 2011
openaire   +2 more sources

Proprotein-Convertases Subtilysin/Hexin Type 1-9 (PCSK 1-9)

2021
openaire   +1 more source

Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibition: A Lipocrinologic Review.

The Journal of the Association of Physicians of India, 2019
This review describes the endocrine impact of proprotein convertase subtilisin kexin 9 (PCSK9) biology and PCSK9 inhibition. It discusses the relationship of the pituitary, thyroid, parathyroid, pancreatic, adrenal and gonadal hormones with lipid health.
openaire   +1 more source

Surf4 regulates expression of proprotein convertase subtilisin/kexin type 9 (PCSK9) but is not required for PCSK9 secretion in cultured human hepatocytes.

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids, 2020
Yishi Shen, Binxiang Wang, Shi-jun Deng, Lei Zhai, Hong-mei Gu, A. Alabi, Xiao-dan Xia, Yongfang Zhao, Xiaole Chang, S. Qin, Da-wei Zhang   +10 more
semanticscholar   +1 more source